The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look ...

For people living with diabetes, vision complications require immediate attention. Diabetic macular edema (DME), a condition ...

Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery -- Multiple Events at Asia-Pacific ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

Age-Related Macular Degeneration market growth analysis. PORTLAND, OR, UNITED STATES, November 21, 2024 /EINPresswire / -- Increase in prevalence of age-re ...

Positive 3-year results from the phase III PHOTON study were presented at the recent American Academy of Ophthalmology (AAO) ...

LUNA Phase 2 Trial and OPTIC First-in-Human Trial - Background and Baseline Prior Anti-VEGF Injections LUNA is an ongoing double-masked, randomized Phase 2 trial. 60 patients with wet AMD were ...

Diabetic retinopathy (DR) is the primary cause of visual impairment among working-age populations in industrialized nations.